<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448589</url>
  </required_header>
  <id_info>
    <org_study_id>TAS-119-102</org_study_id>
    <secondary_id>2014-001272-63</secondary_id>
    <nct_id>NCT02448589</nct_id>
  </id_info>
  <brief_title>An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel</brief_title>
  <official_title>A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic
      and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, non-randomized, dose escalation study of TAS-119 evaluating
      the safety, tolerability, PK, pharmacogenomics, pharmacodynamics, and preliminary antitumour
      activity in patients with advanced and unresectable solid tumours. The study will evaluate
      TAS-119 monotherapy, employing two sequential phases.

        -  A Dose Escalation Phase

        -  An Expansion Phase
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>Up to 2.5 Years</time_frame>
    <description>Identify the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of TAS-119</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>TAS-119 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation:
A Monotherapy Dose-Escalation Phase Performed in Approximately 5 Dose Levels (3 to 12 Patients Per Dose Level) to Determine the MTD for TAS-119 Given Orally (PO), Twice-Daily (BID) in a 28-Day Treatment Cycle; and:
Dose Expansion:
A Monotherapy Expansion Phase in Which Approximately 40 Additional Patients will be Enrolled to Further Evaluate the Recommended Phase II Dose (RP2D)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-119</intervention_name>
    <arm_group_label>TAS-119 Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria include the following:

          1. Is a male or female, ≥ 18 years of age, who has provided written informed consent.

          2. Has histologically or cytologically confirmed advanced, unresectable, metastatic solid
             tumor(s) for which the patients have no available therapy likely to provide clinical
             benefit.

          3. Must have an archival FFPE tumor sample available, to be provided to the Sponsor upon
             request.

          4. In the Expansion Phase: patients should be willing to undergo tumor core biopsy
             procedure at pre-treatment and on Day 4, Cycle 1 if, in the judgment of the
             investigator, it is considered clinically safe and appropriate to do so. This
             requirement is optional but preferred for patients in Dose Escalation.

          5. Has adequate organ function.

        Women of childbearing potential must have a negative pregnancy test (urine or serum) within
        7 days prior to starting the study drug. Both males and females and must agree to use
        effective birth control during the study if conception is possible during this interval.

        Exclusion:

          1. Has received prior treatment with TAS-119.

          2. Has received treatment with any proscribed treatments within specified time frames
             prior to study drug administration.

          3. Has a serious illness or medical condition(s).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Takekazu Aoyama, MD PhD</last_name>
    <phone>1 (609) 750-5300</phone>
    <email>aoyama@taihooncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Taiho Pharmaceutics Europe, Ltd.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals - Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afshin Dowlati, MD</last_name>
      <phone>216-983-3241</phone>
      <email>Afshin.Dowlati@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Afshin Dowlati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Gianni, PhD, MD</last_name>
      <phone>+39 0226436529</phone>
      <email>gianni.luca@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Luca Gianni, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Cancer Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferry ALM Eskens, MD PhD</last_name>
      <phone>+31 10 703 48 97</phone>
      <email>f.eskens@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Ferry ALM Eskens, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START MADRID-FJD, Hospital Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Moreno, PhD, MD</last_name>
      <phone>+34 91 550 48 00</phone>
      <phone_ext>2724</phone_ext>
      <email>Victor.Moreno@start.stoh.com</email>
    </contact>
    <investigator>
      <last_name>Victor Moreno, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Madrid Unidad de Ensayos Fase I</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiliano Calvo, PhD, MD</last_name>
      <phone>+34 91 756 79 31</phone>
      <email>Emiliano.Calvo@start.stoh.com</email>
    </contact>
    <investigator>
      <last_name>Emiliano Calvo, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute of Cancer Research</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann S DeBono, MD</last_name>
      <phone>+44 (0) 208 722 4029</phone>
      <email>Johann.DeBono@icr.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Johann S DeBono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mountzios G, Terpos E, Dimopoulos MA. Aurora kinases as targets for cancer therapy. Cancer Treat Rev. 2008 Apr;34(2):175-82. Epub 2007 Nov 19. Review.</citation>
    <PMID>18023292</PMID>
  </reference>
  <reference>
    <citation>Ogawa E, Takenaka K, Katakura H, Adachi M, Otake Y, Toda Y, Kotani H, Manabe T, Wada H, Tanaka F. Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC). Ann Surg Oncol. 2008 Feb;15(2):547-54. Epub 2007 Nov 28.</citation>
    <PMID>18043979</PMID>
  </reference>
  <reference>
    <citation>Xu HT, Ma L, Qi FJ, Liu Y, Yu JH, Dai SD, Zhu JJ, Wang EH. Expression of serine threonine kinase 15 is associated with poor differentiation in lung squamous cell carcinoma and adenocarcinoma. Pathol Int. 2006 Jul;56(7):375-80.</citation>
    <PMID>16792546</PMID>
  </reference>
  <reference>
    <citation>Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res. 2008 Jul 15;14(14):4455-62. doi: 10.1158/1078-0432.CCR-07-5268.</citation>
    <PMID>18628459</PMID>
  </reference>
  <reference>
    <citation>Lassmann S, Shen Y, Jütting U, Wiehle P, Walch A, Gitsch G, Hasenburg A, Werner M. Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin Cancer Res. 2007 Jul 15;13(14):4083-91.</citation>
    <PMID>17634533</PMID>
  </reference>
  <reference>
    <citation>Lagarde P, Pérot G, Kauffmann A, Brulard C, Dapremont V, Hostein I, Neuville A, Wozniak A, Sciot R, Schöffski P, Aurias A, Coindre JM, Debiec-Rychter M, Chibon F. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res. 2012 Feb 1;18(3):826-38. doi: 10.1158/1078-0432.CCR-11-1610. Epub 2011 Dec 13.</citation>
    <PMID>22167411</PMID>
  </reference>
  <reference>
    <citation>Reiter R, Gais P, Jütting U, Steuer-Vogt MK, Pickhard A, Bink K, Rauser S, Lassmann S, Höfler H, Werner M, Walch A. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res. 2006 Sep 1;12(17):5136-41.</citation>
    <PMID>16951231</PMID>
  </reference>
  <reference>
    <citation>Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 2003 Jan;3(1):51-62.</citation>
    <PMID>12559175</PMID>
  </reference>
  <reference>
    <citation>McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. Review.</citation>
    <PMID>18068131</PMID>
  </reference>
  <reference>
    <citation>Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011 Nov;1(6):487-95. doi: 10.1158/2159-8290.CD-11-0130.</citation>
    <PMID>22389870</PMID>
  </reference>
  <reference>
    <citation>Tajiri T, Tanaka S, Shono K, Kinoshita Y, Fujii Y, Suita S, Ihara K, Hara T. Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. Cancer Lett. 2001 May 10;166(1):89-94.</citation>
    <PMID>11295291</PMID>
  </reference>
  <reference>
    <citation>Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 1;24(19):3187-205. Epub 2006 May 8.</citation>
    <PMID>16682719</PMID>
  </reference>
  <reference>
    <citation>Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, Witt O, Fischer M, Chesler L, Eilers M. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell. 2013 Jul 8;24(1):75-89. doi: 10.1016/j.ccr.2013.05.005. Epub 2013 Jun 20. Erratum in: Cancer Cell. 2016 Aug 8;30(2):357-358.</citation>
    <PMID>23792191</PMID>
  </reference>
  <reference>
    <citation>Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Epub 2009 Sep 25. Review.</citation>
    <PMID>19785645</PMID>
  </reference>
  <reference>
    <citation>Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. doi: 10.1124/pr.110.002857. Epub 2011 Jan 18. Review.</citation>
    <PMID>21245207</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J, Therasse P; RECIST Working Party. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer. 2009 Jan;45(2):248-60. doi: 10.1016/j.ejca.2008.10.027. Epub 2008 Dec 16.</citation>
    <PMID>19095437</PMID>
  </reference>
  <reference>
    <citation>Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55.</citation>
    <PMID>7165009</PMID>
  </reference>
  <reference>
    <citation>Raphael C, Briscoe C, Davies J, Ian Whinnett Z, Manisty C, Sutton R, Mayet J, Francis DP. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart. 2007 Apr;93(4):476-82. Epub 2006 Sep 27.</citation>
    <PMID>17005715</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Dose Escalation</keyword>
  <keyword>Dose Expansion</keyword>
  <keyword>MTD</keyword>
  <keyword>TAS-119</keyword>
  <keyword>Aurora A Kinase Inhibitor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

